Jasper Therapeutics Q3 net loss $11.9M; cash $51M; positive JSP191 data in Fanconi Anemia

Jasper Therapeutics, Inc.

2022-Q3 EPS reported -$0.67

Net loss of $11.9M for Q3 2022 vs $3.4M in Q3 2021; R&D expenses $9.0M, G&A $3.7M.
Cash and equivalents $51.0M as of Sept 30, 2022, expected to fund operations through early 2023.
Positive clinical data: JSP191 conditioning achieved 100% donor chimerism in first two Fanconi Anemia patients.
FDA Fast Track designation granted for JSP191 in Severe Combined Immunodeficiency (SCID) transplant.
Registrational study in AML/MDS and new MDS second-line study expected to start Q1 2023.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Jasper Therapeutics, Inc. reported the quarter ended September 30, 2022 results: net income $11.9 million.

Period: the quarter ended September 30, 2022
Net income: $11.9 million
Result: reported results

Exact text from the filing

Jasper Therapeutics Reports Third Quarter 2022 Financial Results and Provides a Corporate Update

View on SEC.gov

18 earnings releases filed in the last 30 days. Browse all earnings releases →

Jasper Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001213900-22-071153

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.